We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

The Global Fund to Fight AIDS, Tuberculosis and Malaria has announced that future grants will require use of artemisinin — a malaria drug that cures 90 per cent of patients in three days — in place of other therapies, to which the malaria parasite has grown resistant. Until now, people suffering from malaria in Africa have had to make do with inferior — but cheaper — drugs.

The policy change, which also instructs African countries to retrospectively modify existing grants, will cost the fund more than US$1 billion in the next five years. And it will mean that national drug policies will need to be changed across Africa. But grants will be used up more quickly on the drug, which costs ten times more than existing treatments.

Outcry from researchers about donor reluctance to provide artemisinin is partly responsible for the move. In 2002, the World Health Organisation recommended the drug as the treatment of choice. But donors such as the United States and the United Kingdom discouraged its use in Africa on the basis of cost, and only Zambia and Zanzibar have adopted it.

Link to full article in Nature

Reference: Nature 429, 588 (2004)

Related topics